Cancer's notorious ability to hide from immune surveillance may hinge on a previously unknown metabolic modification that directly links tumor energy production to immune escape mechanisms. This discovery reveals how cancer cells weaponize their altered metabolism not just for growth, but for active immune suppression.
The research demonstrates that histone acetyltransferase 1 (HAT1) functions as a lactyltransferase, catalyzing lactylation of the immune checkpoint protein PD-L1. This lactyl modification stabilizes PD-L1 on cancer cell surfaces, enhancing the protein's ability to shut down T-cell responses. The mechanism creates a direct bridge between lactate production—a hallmark of cancer metabolism—and immune checkpoint activation, suggesting tumors co-opt normal metabolic byproducts for defense.
This finding reshapes understanding of how metabolic reprogramming in cancer extends beyond energy production to active immune modulation. Current PD-L1 inhibitors like pembrolizumab have revolutionized cancer treatment, but resistance remains common. The lactylation pathway represents a potential vulnerability that could explain why some tumors resist checkpoint blockade despite high PD-L1 expression. Targeting HAT1's lactyltransferase activity or disrupting the lactylation process could enhance immunotherapy efficacy, particularly in metabolically active tumors with high lactate production. However, this represents early mechanistic research requiring extensive validation before therapeutic applications. The complexity of simultaneously modulating metabolism and immune signaling presents both opportunity and risk, as HAT1 likely has essential cellular functions beyond this newly identified role.